At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 345 enrolled
Drug / intervention
bempedoic acid +1 moredrug
Likely dose
bempedoic acid 180 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180 mg Compared to Placebo Added to Background Lipid-Modifying Therapy in Patients With Elevated LDL-C Who Are Statin Intolerant
In Brief
A Phase 3 clinical trial evaluating bempedoic acid and placebo for Hypercholesterolemia and 2 related conditions. Completed, enrolled 345 participants across 67 sites in 2 countries.
Detailed Summary
The purpose of this study is to determine if bempedoic acid (ETC-1002) is effective and safe versus placebo in patients with elevated LDL cholesterol and who are statin-intolerant.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartNov 2016
First PostedDec 2016
Primary CompletionMar 2018
TodayJul 2026
First PostedDec 9, 2016
Enrollment StartNov 16, 2016
Primary CompletionMar 16, 2018
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 9.6 years ago
Interventions
bempedoic aciddrug
bempedoic acid 180 mg tablet
placeboother
Matching placebo tablet